Cargando…
Novel Epigallocatechin-3-Gallate (EGCG) Derivative as a New Therapeutic Strategy for Reducing Neuropathic Pain after Chronic Constriction Nerve Injury in Mice
Neuropathic pain is common in peripheral nerve injury and often fails to respond to ordinary medication. Here, we investigated whether the two novel epigallocatechin-3-gallate (EGCG) polyphenolic derivatives, compound 23 and 30, reduce the neuropathic pain in mice chronic constriction nerve injury (...
Autores principales: | Xifró, Xavier, Vidal-Sancho, Laura, Boadas-Vaello, Pere, Turrado, Carlos, Alberch, Jordi, Puig, Teresa, Verdú, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391943/ https://www.ncbi.nlm.nih.gov/pubmed/25855977 http://dx.doi.org/10.1371/journal.pone.0123122 |
Ejemplares similares
-
Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury
por: Boadas-Vaello, Pere, et al.
Publicado: (2015) -
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016) -
Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice
por: Castany, Sílvia, et al.
Publicado: (2019) -
Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives
por: Zhong, Ying, et al.
Publicado: (2012) -
Mechanism of (−)-epigallocatechin gallate (EGCG) dimerization by low-temperature plasma
por: Park, Seungil, et al.
Publicado: (2022)